China688276.CG▼
Baike Bio reports first-half net loss attributable to shareholders of about 52.1 million yuan
Baike Bio released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 52.1 million yuan in the first half, narrowing from a loss of about 73.57 million yuan in the same period last year. The company achieved operating revenue of about 305 million yuan in the first half, up 6.89 percent year on year. Baike Bio is a high-tech biopharmaceutical company specializing in the research, development, production and sales of human vaccines, and currently has approved vaccine products including varicella vaccine, nasal spray influenza vaccine, herpes zoster vaccine and liquid nasal spray influenza vaccine.